Menu Search
Equities

NovaBay Pharmaceuticals Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
B9P0:FRA

NovaBay Pharmaceuticals Inc

Actions
  • Price (EUR)0.58
  • Today's Change-0.07 / -10.77%
  • Shares traded2.00k
  • 1 Year change--
  • Beta0.1450
Data delayed at least 15 minutes, as of Feb 11 2026 14:25 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

NovaBay Pharmaceuticals, Inc. is engaged in wound care products. The Company manufactures and sells its proprietary form of hypochlorous acid for the wound care market through its NeutroPhase and PhaseOne branded products. NeutroPhase and PhaseOne are used for cleansing and irrigation as part of surgical procedures, as well as treating wounds, burns, ulcers and other injuries.

  • Revenue in USD (TTM)2.83m
  • Net income in USD-7.95m
  • Incorporated2010
  • Employees14.00
  • Location
    NovaBay Pharmaceuticals Inc2000 Powell St Ste 1150EMERYVILLE 94608-1804United StatesUSA
  • Phone+1 (510) 899-8800
  • Fax+1 (510) 225-0371
  • Websitehttps://novabay.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.